DermTech Balance Sheet Health

Financial Health criteria checks 3/6

DermTech has a total shareholder equity of $40.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $103.0M and $63.0M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$38.98m
EquityUS$39.99m
Total liabilitiesUS$62.98m
Total assetsUS$102.97m

Recent financial health updates

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Sep 18
Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Jun 14
Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02
Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Dec 28
Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Sep 18
Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Jun 14
Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10
Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08
Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11
Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10
Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04
We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02
Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Financial Position Analysis

Short Term Liabilities: DMTK.Q's short term assets ($44.2M) exceed its short term liabilities ($12.5M).

Long Term Liabilities: DMTK.Q's short term assets ($44.2M) do not cover its long term liabilities ($50.5M).


Debt to Equity History and Analysis

Debt Level: DMTK.Q is debt free.

Reducing Debt: DMTK.Q currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if DMTK.Q has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DMTK.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 02:13
End of Day Share Price 2024/12/31 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DermTech, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sally YanchusBrookline Capital Markets
Mark MassaroBTIG
Alexander NowakCraig-Hallum Capital Group LLC